Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Neisseria meningitidis group B LPS/Lipopolysaccharide Antibody (SAA1462)

Catalog #:   RXX02140 Specific References (21) DATASHEET
Host species: Mouse
Isotype: IgG2a
Applications: ELISA
Expression system: Mammalian Cells
Overview

Catalog No.

RXX02140

Expression system

Mammalian Cells

Species reactivity

Neisseria meningitidis group B

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Target

Lipopolysaccharide, Lipid A moiety, LPS

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA1462

Data Image
References

An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity., PMID:26390123

Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum., PMID:25242628

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease., PMID:23273968

Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B., PMID:21768280

Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading., PMID:20340043

Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B., PMID:17908810

Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them., PMID:17712231

Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms., PMID:16288370

Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students., PMID:15501781

Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis., PMID:14688137

Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis., PMID:14530350

Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response., PMID:12933866

Complement activation and formation of the membrane attack complex on serogroup B Neisseria meningitidis in the presence or absence of serum bactericidal activity., PMID:12065518

Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein., PMID:12065469

Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B., PMID:10725453

Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response., PMID:9286048

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia., PMID:8627067

Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines., PMID:8559044

Cloning and molecular analysis of the galE gene of Neisseria meningitidls and its role in lipopolysaccharide biosynthesis., PMID:28776852

Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis., PMID:7934827

Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay., PMID:2510417

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Neisseria meningitidis group B LPS/Lipopolysaccharide Antibody (SAA1462) [RXX02140]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only